Joint meeting of the 26th Drug Design & Development Seminar (DDDS) 2026 of the German Society for Parasitology (DGP) & The European Cost Action – CA21111 – “OneHealthDrugs”

About the Drug Design & Development Seminar (DDDS) 

The Drug Design & Development Seminar (DDDS) was founded in 1999 as an active working group of the German Society for Parasitology, by Prof. Dr. Peter Köhler (Univ. of Zürich, CH), Prof. Dr. Rolf Walter (BNI, Hamburg, DE), and Prof. Dr. Heiner Schirmer (Univ. of Heidelberg, DE). Since 2004 Prof. Dr. Paul M. Selzer (Boehringer Ingelheim Animal Health, Ingelheim, DE) is the coordinator of the DDDS transferring the meeting into an international well recognized scientific forum. Exchange of scientific information about anti-parasitic chemotherapy between universities, industry, and other research organizations continues to be important to accelerate anti-parasitic drug development. The DDDS is open to all scientists and professionals interested in the field of anti-parasitic research. The DDDS aims at connecting human and veterinary health by complementary approaches in medical and veterinary parasitology and medicinal chemistry to aim and stimulate One-Health approaches to combat parasitic diseases. The main topics include but are not limited to: 

- Target identification, characterization, and validation 

- Identification of compounds 

- Synthesis and optimization of lead compounds towards marketable drugs 

- Testing active compounds in animal models 

About the Cost Action CA21111 / OneHealthdrugs 

OneHealthdrugs aims to coordinate the discovery of drugs that stop vector-borne infections in both human and veterinary settings according to the principles of the optimal profile for both organisms, increasing quality and reducing environmental impact. The COST Action is a platform aiming at the integration and generation of synergies among drug R&D experts from the chemical / biological / human / veterinary and earth science within academies, SMEs, industries, governments. The platform encompasses pre-clinical drug discovery, animal studies, and drug delivery. Strategies such as bioinformatics, PROTACs, nanotechnology will be enhanced. OneHealthdrugs impacts in Europe and in disease-endemic countries. The action provides a compound database and a white chart about the discovery of new drugs for human and animal infections.